Veracyte Inc
(FRA:12V)
€
39.4
0.8 (2.07%)
Market Cap: 3.16 Bil
Enterprise Value: 2.92 Bil
PE Ratio: 0
PB Ratio: 2.76
GF Score: 81/100 Veracyte Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 10:20PM GMT
Release Date Price:
€24.6
(+3.36%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Welcome, everybody. Good afternoon. My name is Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. I've got the pleasure of hosting the Veracyte management team here with me today: CEO, Marc Stapley; and CFO, Rebecca Chambers. Marc, Rebecca, thank you very much for joining us.
Marc A. Stapley
Veracyte, Inc. - CEO & Director
Thank you for having us.
Rebecca Chambers
Veracyte, Inc. - Executive VP & CFO
Thank you for having us.
Questions & Answers
Matthew Carlisle Sykes;Marc A. Stapley
Goldman Sachs Group, Inc., Research Division - Research Analyst;Veracyte, Inc. - CEO
Maybe if you could just kind of help us set the stage first, talk a little bit about sort of the most recent results, some of the trends you're seeing in your business and what you're kind of expecting for the second half of this year.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot